Advertisement

Table of Contents

Priority Briefs

  • Priority Briefs
    Molecular Drivers of the Non–T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer
    Randy F. Sweis, Stefani Spranger, Riyue Bao, Gladell P. Paner, Walter M. Stadler, Gary Steinberg and Thomas F. Gajewski
    Cancer Immunol Res July 1 2016 4 (7) 563-568; DOI:10.1158/2326-6066.CIR-15-0274

    Immunotherapy resistance is a reality for many cancer patients. Three tumor-intrinsic molecular pathways, β-catenin, PPARγ, and FGFR3, were identified and linked to the exclusion of T cells from urothelial tumors. Targeting these pathways may enhance immune checkpoint efficacy.

  • Priority Briefs
    Prolonged Benefit from Ipilimumab Correlates with Improved Outcomes from Subsequent Pembrolizumab
    Amanda Shreders, Richard Joseph, Chengwei Peng, Fei Ye, Shilin Zhao, Igor Puzanov, Jeffrey A. Sosman and Douglas B. Johnson
    Cancer Immunol Res July 1 2016 4 (7) 569-573; DOI:10.1158/2326-6066.CIR-15-0281

    Anti–PD-1 therapies are becoming first-line treatments for metastatic melanoma, but how prior immune therapy affects anti–PD-1 efficacy is unknown. Prior ipilimumab was found to predict response to anti–PD-1, which could help select patients for therapy.

Research Articles

  • Research Articles
    Expanded and Activated Natural Killer Cells for Immunotherapy of Hepatocellular Carcinoma
    Takahiro Kamiya, Yu-Hsiang Chang and Dario Campana
    Cancer Immunol Res July 1 2016 4 (7) 574-581; DOI:10.1158/2326-6066.CIR-15-0229

    Hepatocellular carcinoma (HCC) is often incurable. Human NK cells with enhanced cytotoxicity against HCC were expanded in vitro, generating efficient killers of HCC in culture and in mice, supporting the infusion of such cells for treatment of HCC.

  • Research Articles
    Immune-Derived PD-L1 Gene Expression Defines a Subgroup of Stage II/III Colorectal Cancer Patients with Favorable Prognosis Who May Be Harmed by Adjuvant Chemotherapy
    Philip D. Dunne, Darragh G. McArt, Paul G. O'Reilly, Helen G. Coleman, Wendy L. Allen, Maurice Loughrey, Sandra Van Schaeybroeck, Simon McDade, Manuel Salto-Tellez, Daniel B. Longley, Mark Lawler and Patrick G. Johnston
    Cancer Immunol Res July 1 2016 4 (7) 582-591; DOI:10.1158/2326-6066.CIR-15-0302

    A subgroup of patients with colorectal cancer was defined by high PD-L1 gene expression on their tumor-infiltrating immune cells. These patients may be harmed by standard chemotherapy and may benefit from immunotherapy that targets the PD-1 immune checkpoint.

  • Research Articles
    Pretreatment Immune Status Correlates with Progression-Free Survival in Chemotherapy-Treated Metastatic Colorectal Cancer Patients
    Kohei Tada, Shigehisa Kitano, Hirokazu Shoji, Takashi Nishimura, Yasuhiro Shimada, Kengo Nagashima, Kazunori Aoki, Nobuyoshi Hiraoka, Yoshitaka Honma, Satoru Iwasa, Natsuko Okita, Atsuo Takashima, Ken Kato, Yasuhide Yamada, Naoyuki Katayama, Narikazu Boku, Yuji Heike and Tetsuya Hamaguchi
    Cancer Immunol Res July 1 2016 4 (7) 592-599; DOI:10.1158/2326-6066.CIR-15-0298

    It was not clear whether immune cell subsets in peripheral blood have prognostic value for patients about to undergo first-line chemotherapy. This prospective study reveals an immune signature that correlates with significantly longer progression-free survival.

  • Research Articles | AuthorChoice
    Immunogenic Subtypes of Breast Cancer Delineated by Gene Classifiers of Immune Responsiveness
    Lance D. Miller, Jeff A. Chou, Michael A. Black, Cristin Print, Julia Chifman, Angela Alistar, Thomas Putti, Xiaobo Zhou, Davide Bedognetti, Wouter Hendrickx, Ashok Pullikuth, Jonathan Rennhack, Eran R. Andrechek, Sandra Demaria, Ena Wang and Francesco M. Marincola
    Cancer Immunol Res July 1 2016 4 (7) 600-610; DOI:10.1158/2326-6066.CIR-15-0149

    Assessment of expression profiles and clinical data from many breast tumors enabled classifications having prognostic value. Tumors comprising molecularly distinct subtypes differed in potential for metastasis-protective immune responsiveness, perhaps reflecting a differential activation of immunomodulatory pathways

  • Research Articles
    Enhanced Tumor Control with Combination mTOR and PD-L1 Inhibition in Syngeneic Oral Cavity Cancers
    Ellen C. Moore, Harrison A. Cash, Andria M. Caruso, Ravindra Uppaluri, James W. Hodge, Carter Van Waes and Clint T. Allen
    Cancer Immunol Res July 1 2016 4 (7) 611-620; DOI:10.1158/2326-6066.CIR-15-0252

    Inhibition of mTOR is felt to be systemically immunosuppressive. However, the antitumor immunity induced by checkpoint inhibition in an immunogenic model of oral cavity cancer was enhanced by the mTOR inhibitor rapamycin via a T cell–dependent mechanism.

  • Research Articles
    Antitumor Efficacy of Radiation plus Immunotherapy Depends upon Dendritic Cell Activation of Effector CD8+ T Cells
    Simon J. Dovedi, Grazyna Lipowska-Bhalla, Stephen A. Beers, Eleanor J. Cheadle, Lijun Mu, Martin J. Glennie, Timothy M. Illidge and Jamie Honeychurch
    Cancer Immunol Res July 1 2016 4 (7) 621-630; DOI:10.1158/2326-6066.CIR-15-0253

    Radiotherapy plus CD40 or TLR7 stimulation leads to long-term clearance of B- and T-cell lymphomas. These curative responses after combining radiotherapy with an immunomodulatory agent depended upon the priming of tumor-specific CD8+ T cells by dendritic cells.

  • Research Articles
    Antitumor Efficacy of Anti-GD2 IgG1 Is Enhanced by Fc Glyco-Engineering
    Hong Xu, Hongfen Guo, Irene Y. Cheung and Nai-Kong V. Cheung
    Cancer Immunol Res July 1 2016 4 (7) 631-638; DOI:10.1158/2326-6066.CIR-15-0221

    Most effective antibody immunotherapy relies on ADCC. A potent ADCC-enhanced antibody is described that, in comparison with Abs with altered affinities for Fc receptors, significantly improved the growth control of tumors expressing cancer-antigen GD2.

Addendum

Back to top
Cancer Immunology Research: 4 (7)
July 2016
Volume 4, Issue 7

Sign up for alerts

Jump to

Advertisement